2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P3624
    Cenderitide 507289-11-4 99.84%
    Cenderitide is a potent agonist of particulate guanylyl cyclase receptor (pGC). Cenderitide is a natriuretic peptide (NP) composed of C-type natriuretic peptide (CNP) fused to the C-terminus of Dendroaspis natriuretic peptide (DNP). Cenderitide activates both pGC-A and pGC-B, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure. Cenderitide can be used for heart failure research.
    Cenderitide
  • HY-P3769
    Prepro-ANF (56-92), human 112199-06-1 99.93%
    Prepro-ANF (56-92), human is a human atrial natriuretic factor precursor. Prepro-ANF (56-92), human is also a guanylate cyclase activator that enhances particulate guanylate cyclase activity in the renal membrane and renal unit.
    Prepro-ANF (56-92), human
  • HY-Y0106
    2,6-Dihydroxyacetophenone 699-83-2
    2,6-Dihydroxyacetophenone, a polyphenolic derivative of Acetophenone (HY-Y0989), is an orally active mTOR inhibitor. 2,6-Dihydroxyacetophenone shows antioxidant activity. 2,6-Dihydroxyacetophenone inhibits cell growth and proliferation in CRC cells. 2,6-Dihydroxyacetophenone arrests at G0/G1 phase of cell cycle, induces apoptosis and suppresses cell migration in CRC cells. 2,6-Dihydroxyacetophenone inhibits xanthine oxidase (XOD) with an IC50 of 1.24 mM. 2,6-dihydroxyacetophenone improves uric acid metabolism in hyperuricemia mice, reduces plasma cholesterol in hypercholesterolemic rats, and inhibits lipid accumulation in HFD-induced obese mice. 2,6-Dihydroxyacetophenone can be used for the study of colorectal cancer (CRC), hyperuricemia and hypercholesterolemia.
    2,6-Dihydroxyacetophenone
  • HY-100276
    Naminidil 220641-11-2 99.62%
    Naminidil is a cyanoguanidine KATP opener.
    Naminidil
  • HY-100655
    O-Desmethyl apixaban 503612-76-8 99.51%
    O-Desmethyl apixaban is a metabolite of Apixaban (BMS-562247-01). Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively.
    O-Desmethyl apixaban
  • HY-100952
    Nifenalol hydrochloride 5704-60-9 99.93%
    Nifenalol hydrochloride is a β-adrenergic receptor antagonist. Nifenalol hydrochloride induces the Early Afterdepolarization (EAD) effect. EAD is a phenomenon in cardiac electrophysiology that usually occurs during an action potential in ventricular muscle cells and can lead to arrhythmia. The EAD effect of Nifenalol hydrochloride can be blocked by Tetrodotoxin. Nifenalol hydrochloride is used in the study of conditions such as irregular heartbeat or high blood pressure.
    Nifenalol hydrochloride
  • HY-100967
    SKF 91488 dihydrochloride 68941-21-9 98.62%
    SKF 91488 (Homodimaprit) dihydrochloride is a potent and noncompetitive histamine N-methyltransferase inhibitor with a Ki value of 0.9 μM. SKF 91488 dihydrochloride can block histamine metabolism and increase histamine concentrations. SKF 91488 dihydrochloride can increase blood pressure and enhance bronchoconstriction. SKF 91488 can be used for the researches of infection, inflammation and cardiovascular disease, such as Mycoplasma pneumonia and hemorrhagic hypotension.
    SKF 91488 dihydrochloride
  • HY-101069
    Y-26763 127408-31-5 99.7%
    Y-26763 is a K+ channel opener and active metabolite of Y-27152. Y-26763 is an ATP-sensitive K+ (KATP) channel activator.
    Y-26763
  • HY-102029
    Sarafotoxin S6c 121695-87-2 98.19%
    Sarafotoxin S6c (SRTX-c) is a potent endothelin-B receptor agonist. Sarafotoxin S6c can cause vasoconstriction in both endothelium-intact and endothelium-denuded vessels.
    Sarafotoxin S6c
  • HY-102093
    ZD 7155(hydrochloride) 146709-78-6 99.88%
    ZD 7155 hydrochloride is an angiotensin II receptor type 1 (AT1 receptor) antagonist.
    ZD 7155(hydrochloride)
  • HY-103174
    MRS1334 192053-05-7 98.93%
    MRS1334 is a potent and selective human adenosine A3 receptor antagonist with Kis of 2.69 nM, >100 nM, >100 nM for hA3, rA1, rA2A, respectively. MRS1334 blocks the protective effect of Cl-IB-MECA leading to significant bradycardia and elevated ST segment. MRS1334 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    MRS1334
  • HY-103445
    SSR69071 344930-95-6 98.4%
    SSR69071 is a potent, orally active and selective inhibitor of neutrophil elastase. SSR69071 reduces myocardial infarct size following ischemia-reperfusion injury. SSR69071 displays a higher affinity for human elastase (Ki=0.0168 nM) than for rat (Ki=3 nM), mouse (Ki=1.8 nM), and rabbit (Ki= 58 nM) elastases.
    SSR69071
  • HY-103484
    GATA4-NKX2-5-IN-1 544681-96-1 99.24%
    GATA4-NKX2-5-IN-1 (Compound 3) dose-dependently inhibits the GATA4–NKX2-5 transcriptional synergy with an IC50 of 3 μM. GATA4-NKX2-5-IN-1 exhibits no activity on the protein kinases involved in the regulation of GATA4 phosphorylation, and it modulates the hypertrophic agonist-induced cardiac gene expression.
    GATA4-NKX2-5-IN-1
  • HY-105064
    Zoniporide 241800-98-6 99.89%
    Zoniporide (CP-597396) is a potent and selective NHE-1 inhibitor with cardioprotective activity. Zoniporide inhibits 22Na+ uptake by human NHE-1-expressing fibroblasts in a concentration-dependent manner (IC50=14 nM). Zoniporide inhibits platelet swelling in vitro with an IC50 of 0.059 μM. Zoniporide can be used in the study of cardiovascular disease.
    Zoniporide
  • HY-105068
    Apadenoson 250386-15-3 99.05%
    Apadenoson is an adenosine analog with selective agonist activity for the adenosine A2a receptor and induces coronary vasodilatation.
    Apadenoson
  • HY-105858
    H-Ile-Trp-OH 13589-06-5 98.04%
    H-Ile-Trp-OH (Ile-Trp), a dipeptide, is an angiotensin-converting enzyme (ACE) inhibitor with an IC50 of 0.7 μM. H-Ile-Trp-OH inhibits predominantly the C-domain of ACE.
    H-Ile-Trp-OH
  • HY-106045
    Imazodan 84243-58-3 99.38%
    Imazodan is a selective inhibitor for phosphodiesterase III (PDE III), which increases myocardial contractility by blocking the cAMP degradation, and improves the contractile function of heart. Imazodan serves also as a peripheral vasodilator.
    Imazodan
  • HY-106130
    Implitapide 177469-96-4 99.87%
    Implitapide (AEGR 427) is a microsomal triglyceride transfer protein (MTP) inhibitor.
    Implitapide
  • HY-107260
    Lucidenic acid D 98665-16-8 99.78%
    Lucidenic acid D (Lucidenic acid D2) is a highly oxidized lanostane-type triterpenoid, can inhibit the proliferation of HepG2 cells.
    Lucidenic acid D
  • HY-107655
    Arecaidine but-2-ynyl ester tosylate 119630-77-2 99.95%
    Arecaidine but-2-ynyl ester tosylate (ABET) is a selective mAChR M2 agonist that dose-dependently decreases mean arterial pressure and heart rate in rats. Arecaidine but-2-ynyl ester tosylate can be used for cardiovascular disease research. Arecaidine but-2-ynyl ester (tosylate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Arecaidine but-2-ynyl ester tosylate
Cat. No. Product Name / Synonyms Application Reactivity